Insulin allergy: Clinical manifestations and management strategies

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 2, 2008, Pages 148-155

  Heinzerling, L ^a,b   Raile, K ^a   Rochlitz, H ^a   Zuberbier, T ^a   Worm, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Drug reaction; IgE; Skin prick test; Specific immunotherapy; Tolerance; Type 1 allergic reaction

Indexed keywords

ACTRAPID PENFILL; ACTRAPID SUIS MC; ANTIHISTAMINIC AGENT; APIDRA OPTISET; BASAL HOECHST; BERLINSULIN BASAL; BERLINSULIN H 30/70; BOVINE INSULIN; CORTICOSTEROID; CRESOL; DRUG ADDITIVE; GLYCEROL; HUMALOG MIX; HUMINSULIN BASAL; HUMINSULIN PROFIL 30/70; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; INSULIN; INSULIN ASPART; INSULIN B BRAUN; INSULIN B BRAUN BASAL; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN S BERLIN CHEMIE; INSULIN SNC BERLIN CHEMIE; INSULIN ZINC SUSPENSION; INSUMAN INFUSAT; INSUMAN RAPID; ISOPHANE INSULIN; LATEX; METHYL PARABEN; NEUTRAL INSULIN; NOVO RAPID; NOVO RAPID PENFILL; NOVO ULTRATARD; ORAL ANTIDIABETIC AGENT; PENICILLIN G; PENICILLIN V; PHENOL; PIG INSULIN; PROTAMINE; RECOMBINANT HUMAN INSULIN; TROMETAMOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ALLERGY TEST; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CONFUSION; DIABETES MELLITUS; DIPLOPIA; DYSPNEA; FLUSHING; HEART PALPITATION; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; INSULIN ALLERGY; INSULIN RESISTANCE; INSULIN TREATMENT; LOW DRUG DOSE; MALAISE; PALLOR; PARESTHESIA; PRICK TEST; PRIORITY JOURNAL; PRURITUS; RARE DISEASE; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SYMPTOM; URTICARIA;

ADOLESCENT; ADULT; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; INSULIN; MALE; MIDDLE AGED; SKIN TESTS;

EID: 37749001731     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01567.x     Document Type: Review

References (62)

1. Fernandez L, Duque S, Montalban C, Bartolome B. Allergy to human insulin. Allergy 2003 58 : 1317.
2. Blanco C, Castillo R, Quiralte J, Delgado J, García I, de Pablos P et al. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. Allergy 1996 51 : 421 424.
3. deShazo RD, Boehm TM, Kumar D, Galloway JA, Dvorak HF. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. J Allergy Clin Immunol 1982 69 : 229 237.
4. Mandrup-Poulsen T, Molvig J, Pildal J, Rasmussen AK, Andersen L, Skov BG et al. Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia. Diabetes Care 2002 25 : 242 243.
5. Feinglos MN, Jegasothy BV. "Insulin" allergy due to zinc. Lancet 1979 1 : 122 124.
6. Raap U, Liekenbrocker T, Kapp A, Wedi B. Delayed-type hypersensitivity to protamine as a complication of insulin therapy. Contact Dermatitis 2005 53 : 57 58.
7. Goldfine AB, Kahn CR. Insulin allergy and insulin resistance. Curr Ther Endocrinol Metab 1994 5 : 461 464.
8. Kaya A, Gungor K, Karakose S. Severe anaphylactic reaction to human insulin in a diabetic patient. J Diabetes Complications 2007 21 : 124 127.
9. Chng HH, Leong KP, Loh KC. Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy 1995 50 : 984 987.
10. Gonzalo MA, de Argila D, Revenga F, Garcia JM, Diaz J, Morales F. Cutaneous allergy to human (recombinant DNA) insulin. Allergy 1998 53 : 106 107.
11. Wessbecher R, Kiehn M, Stoffel E, Moll I. Management of insulin allergy. Allergy 2001 56 : 919 920.
12. Baur X, Bossert J, Koops F. IgE-mediated allergy to recombinant human insulin in a diabetic. Allergy 2003 58 : 676 678.
13. Scheer BG, Sitz KV. Suspected insulin anaphylaxis and literature review. J Ark Med Soc 2001 97 : 311 313.
14. Lee AY, Chey WY, Choi J, Jeon JS. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002 82 : 114 117.
15. Jaeger C, Eckhard M, Brendel MD, Bretzel RG. Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy. Exp Clin Endocrinol Diabetes 2004 112 : 416 421.
16. Rajpar SF, Foulds IS, Abdullah A, Maheshwari M. Severe adverse cutaneous reaction to insulin due to cresol sensitivity. Contact Dermatitis 2006 55 : 119 120.
17. Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care 2001 24 : 2000.
18. Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997 20 : 1357 1359.
19. Lluch-Bernal M, Fernandez M, Herrera-Pombo JL, Sastre J. Insulin lispro, an alternative in insulin hypersensitivity. Allergy 1999 54 : 186 187.
20. Moriyama H, Nagata M, Fujihira K, Yamada K, Chowdhury SA, Chakrabarty S et al. Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care 2001 24 : 411 412.
21. Panczel P, Hosszufalusi N, Horvath MM, Horvath A. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000 55 : 409 410.
22. Barranco R, Herrero T, Tornero P, Barrio M, Frutos C, Rodriguez A et al. Systemic allergic reaction by a human insulin analog. Allergy 2003 58 : 536 537.
23. Durand-Gonzalez KN, Guillausseau N, Pecquet C, Gayno JP. Glargine insulin is not an alternative in insulin allergy. Diabetes Care 2003 26 : 2216.
24. JiXiong X, Jianying L, Yulan C, Huixian C. The human insulin analog aspart can induce insulin allergy. Diabetes Care 2004 27 : 2084 2085.
25. Takata H, Kumon Y, Osaki F, Kumagai C, Arii K, Ikeda Y et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 2003 26 : 253 254.
26. Blumer IR. Severe injection site reaction to insulin detemir. Diabetes Care 2006 29 : 946.
27. Darmon P, Castera V, Koeppel MC, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care 2005 28 : 2980.
28. Sola-Gazagnes A, Pecquet C, M'Bemba J, Larger E, Slama G. Type I and type IV allergy to the insulin analogue detemir. Lancet 2007 369 : 637 638.
29. Dejgaard A, Larsen J, Pedersen CR. Type I and type IV allergy to insulin detemir. Lancet 2007 369 : 1926 1927.
30. Eapen SS, Connor EL, Gern JE. Insulin desensitization with insulin lispro and an insulin pump in a 5-year-old child. Ann Allergy Asthma Immunol 2000 85 : 395 397.
31. Moyes V, Driver R, Croom A, Mirakian R, Chowdhury TA. Insulin allergy in a patient with type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006 23 : 204 206.
32. Naf S, Esmatjes E, Recasens M, Valero A, Halperin I, Levy I et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002 25 : 634 635.
33. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med 1997 36 : 575 578.
34. Radermecker RP, Scheen AJ. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007 23 : 348 355.
35. Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract 2003 61 : 161 166.
36. Asai M, Yoshida M, Miura Y. Immunologic tolerance to intravenously injected insulin. N Engl J Med 2006 354 : 307 309.
37. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993 16 (Suppl. 3 155 165.
38. Grammer L. Insulin allergy. Clin Rev Allergy 1986 4 : 189 200.
39. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci 1997 86 : 517 525.
40. Maislos M, Mead PM, Gaynor DH, Robbins DC. The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin. J Clin Invest 1986 77 : 717 723.
41. Alvarez-Thull L, Rosenwasser LJ, Brodie TD. Systemic allergy to endogenous insulin during therapy with recombinant DNA (rDNA) insulin. Ann Allergy Asthma Immunol 1996 76 : 253 256.
42. Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung 1999 28 : 418 428.
43. Bollinger ME, Hamilton RG, Wood RA. Protamine allergy as a complication of insulin hypersensitivity: a case report. J Allergy Clin Immunol 1999 104 : 462 465.
44. Clerx V, Van Den KC, Kochuyt A, Goossens A. Drug intolerance reaction to insulin therapy caused by metacresol. Contact Dermatitis 2003 48 : 162 163.
45. Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979 2 : 283 295.
46. Ratner RE, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes 1990 39 : 728 733.
47. Yip CM, Brader ML, DeFelippis MR, Ward MD. Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure. Biophys J 1998 74 : 2199 2209.
48. Madero MF, Sastre J, Carnes J, Quirce S, Herrera-Pombo JL. IgG(4)-mediated allergic reaction to glargine insulin. Allergy 2006 61 : 1022 1023.
49. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003 33 : 1205 1214.
50. Child DF, Johansson SG. IgE antibody studies in a case of generalized allergic reaction to human insulin. Allergy 1984 39 : 630 633.
51. Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med 2005 22 : 102 106.
52. Danne T, Niggemann B, Weber B, Wahn U. Prevalence of latex-specific IgE antibodies in atopic and nonatopic children with type I diabetes. Diabetes Care 1997 20 : 476 478.
53. Roest MA, Shaw S, Orton DI. Insulin-injection-site reactions associated with type I latex allergy. N Engl J Med 2003 348 : 265 266.
54. Velcovsky HG, Federlin KF. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 1982 5 (Suppl. 2 126 128.
55. Jegasothy BV. Allergic reactions to insulin. Int J Dermatol 1980 19 : 139 141.
56. Sharath MD, Metzger WJ, Richerson HB, Scupham RK, Meng RL, Ginsberg BH et al. Protamine-induced fatal anaphylaxis. Prevalence of antiprotamine immunoglobulin E antibody. J Thorac Cardiovasc Surg 1985 90 : 86 90.
57. Stewart WJ, McSweeney SM, Kellett MA, Faxon DP, Ryan TJ. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation 1984 70 : 788 792.
58. Grant W, deShazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diabetes Care 1986 9 : 318 319.
59. Mattson JR, Patterson R, Roberts M. Insulin therapy in patients with systemic insulin allergy. Arch Intern Med 1975 135 : 818 821.
60. Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001 18 : 515 516.
61. Frigerio C, Aubry M, Gomez F, Graf L, Dayer E, de Kalbermatten N et al. Desensitization-resistant insulin allergy. Allergy 1997 52 : 238 239.
62. Witters LA, Ohman JL, Weir GC, Raymond LW, Lowell FC. Insulin antibodies in the pathogenesis of insulin allergy and resistance. Am J Med 1977 63 : 703 709.